DOCSLIB.ORG

Topical Corticosteroids (Cont.) Neuraminidase Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topical Corticosteroids (Cont.) Neuraminidase Inhibitors October 2015, Volume 7, Issue 1 The Prescriber e-Letter October 2015, Volume 7, Issue 1 Topical Corticosteroids (cont.) Neuraminidase inhibitors The neuraminidase inhibitors zanamivir (Relenza®) and The prior authorization process for topical corticosteroids oseltamivir (Tamiflu®) are approved by the U.S. Food and was implemented on October 26, 2015. The PA status of the Drug Administration (FDA) for the prophylaxis and individual products is outlined below. treatment of influenza and have demonstrated activity against both influenza A and influenza B. These agents interfere with PA No PA the release of progeny influenza virus from infected cells, Class I. Super Potent thereby preventing new rounds of infection. A 2003 meta- Clobetasol propionate cream, Betamethasone augmented gel analysis of 17 treatment and seven prevention trials ointment (Temovate®) Betamethasone dipropionate lotion, concluded that these drugs reduced the median duration of Clobetasol propionate foam (Olux®) ointment symptoms by approximately one day and may reduce the Clobetasol propionate foam / Betamethasone dipropionate, odds of developing influenza by 70 to 90%. However, recent emollient (Olux-E®) augmented ointment (Diprolene®)# trials and meta-analyses have demonstrated conflicting Clobetasol propionate lotion, Clobetasol propionate/emollient results on the ability of these agents to reduce influenza- shampoo, spray (Clobex®) (Temovate E®) related complications. Therefore, prior authorization will be Halobetasol cream, ointment Clobetasol propionate gel, solution ® # required for quantities greater than one treatment course per (Ultravate ) Clobetasol propionate shampoo kit season. Diflorasone ointment Fluocinonide 0.1% cream (Vanos®) Flurandrenolide tape (Cordran®) The prior authorization process for neuraminidase inhibitors Halobetasol / lactic acid (Ultravate was implemented on October 26, 2015, and is outlined X®) below. All agents require a PA from June 1 to September 30. From October 1 to May 31, a PA will be required for doses Class II. Potent exceeding the quantity limit as noted in the table below. Amcinonide ointment Betamethasone dipropionate cream Zanamivir requires PA for members <5 years of age. Desoximetasone 0.25% cream, Betamethasone dipropionate, ointment, spray, 0.05% gel augmented cream (Diprolene AF®)# (Topicort®) Betamethasone dipropionate, Drug PA for Quantity Limits ® # ® Diflorasone cream/emollient augmented lotion (Diprolene ) Zanamivir (Relenza ) > 20 inhalations/season ® ® (Apexicon-E ) Fluocinonide cream, gel, ointment, Oseltamivir 30 mg (Tamiflu ) > 20 capsules/season Halcinonide cream, ointment solution Oseltamivir 45 mg and 75 mg > 10 capsules/season (Halog®) Mometasone ointment (Elocon®) (Tamiflu®) Triamcinolone 0.5% ointment Oseltamivir 6 mg/mL > 180 mL/season ® Class III. Upper Mid-Strength Potent suspension (Tamiflu ) Amcinonide cream Amcinonide lotion Betamethasone valerate foam Betamethasone valerate ointment (Luxiq®) Fluocinonide / emollient Topical Corticosteroids Desoximetasone 0.05% cream, Fluticasone ointment ® ointment (Topicort ) Triamcinolone 0.1% ointment, 0.5% ® Topical corticosteroids are FDA-approved for the treatment Diflorasone cream (Psorcon ) cream of a variety of dermatological conditions. The topical Class IV. Mid-Strength Potent corticosteroids were subdivided in the former classification Clocortolone cream (Cloderm®) Fluocinolone ointment (Synalar®)# system of four groups: low potency, medium potency, high Fluocinolone ointment kit (Synalar®) Hydrocortisone valerate ointment potency and very high potency. The USA classification Triamcinolone 0.05% ointment Mometasone cream, solution system subdivides topical corticosteroids into seven classes, Triamcinolone spray (Kenalog®) (Elocon®)# with group one being super potent and group seven being Triamcinolone 0.1% cream least potent. MassHealth has determined that more costly topical corticosteroids will require PA, including all brand- name and generic products that are more costly than comparable alternatives. The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program. The Prescriber e-Letter October 2015, Volume 7, Issue 1 Topical Corticosteroids (cont.) Class V. Lower Mid-Strength Potent Hydrocortisone solution Hydrocortisone cream, lotion, Fluocinolone cream kit (Synalar®) Betamethasone valerate cream ointment Fluocinolone shampoo (Capex®) Desonide lotion, ointment Combination Products Fluticasone lotion (Cutivate®) Fluocinolone 0.01% cream Betamethasone/calcipotriene Hydrocortisone/pramoxine foam Hydrocortisone probutate cream Fluocinolone 0.025% cream ® ® # ointment, scalp suspension (Pandel ) (Synalar ) ® (Taclonex ) Fluticasone cream (Cutivate®)# Neomycin/fluocinolone cream, Hydrocortisone butyrate/emollient cream kit Hydrocortisone butyrate cream, #This designates a brand-name drug with FDA “A”-rated generic ointment, solution Hydrocortisone valerate cream equivalents. PA is required for the brand, unless a particular form of that Prednicarbate cream, ointment drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated (Dermatop®)# generic equivalent. Triamcinolone 0.1% lotion, 0.025% ointment Class VI. Mild Potent Fluocinolone solution kit (Synalar®) Alclometasone cream, ointment Desonide gel (Desonate®) Betamethasone valerate lotion Desonide cream Fluocinolone body oil, scalp oil (Derma-smoothe-FS®)# Fluocinolone solution (Synalar®)# Fluticasone cream, ointment (Cutivate®)# Triamcinolone 0.025% cream, lotion Recent MassHealth Drug List Updates Drug/Drug Class Addition/Deletion/Change Rationale Antihypertensives Change in PA status; does not Given a recent decrease in the cost of the associated generic require PA irbesartan, irbesartan/hydrochlorothiazide, valsartan and valsartan/hydrochlorothiazide products, these agents no Irbesartan/hydrochlorothiazide longer require PA. (Avalide®)# Irbesartan (Avapro®)# Valsartan (Diovan®)# Valsartan/hydrochlorothiazide (Diovan HCT®)# #This designates a brand-name drug with FDA “A”-rated generic equivalents. PA is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent. Change in PA status; requires PA Given the significant increase in the cost of generic captopril, captopril/ hydrochlorothiazide and nadolol, these agents will Captopril require PA due to the availability of less costly alternatives. Captopril/hydrochlorothiazide Nadolol (Corgard®) Anti-inflammatory Ophthalmic Change in PA status; does not Given the rising cost of generic alternatives, fluorometholone Agents require PA acetate and prednisolone sodium phosphate no longer require PA. Fluorometholone acetate (Flarex®) Prednisolone sodium phosphate 1% ophthalmic solution 2 The Prescriber e-Letter October 2015, Volume 7, Issue 1 Antiviral Agents Change in PA status; requires PA PA will be required for quantities greater than one treatment for exceeding new quantity limits course per season. This will allow for the evaluation of the Zanamivir (Relenza®) –PA < 5 level of risk for complications of influenza infection for years of age and > 20 greater quantities. inhalations/season Oseltamivir 30 mg (Tamiflu®) –PA These agents require PA for all quantities from June 1to > 20 capsules/season September 30. From October 1 to May 31, a PA is required Oseltamivir 45 mg and 75 mg for doses exceeding the quantity limit as outlined. Zanamivir (Tamiflu®) –PA > 10 requires PA for members <5 years of age. capsules/season Oseltamivir 6 mg/mL suspension (Tamiflu®) –PA > 180 mL/season Dermatological Agents Change in PA status; does not Ammonium lactate is indicated for dry skin dermatitis and require PA congenital ichthyosis of the skin and is a brand-name drug with FDA “A”-rated generic equivalents. These agents no Ammonium lactate (Lac-Hydrin®)# longer require PA. Ammonium lactate (LAClotion®)# #This designates a brand-name drug with FDA “A”-rated generic equivalents. PA is required for the brand, unless a particular form of that drug (for example, tablet, capsule, or liquid) does not have an FDA “A”-rated generic equivalent. Insulin Products Addition; requires PA Insulin glargine 300 units/mL prefilled syringe is a higher potency formulation of insulin glargine. This agent requires a Insulin glargine prefilled syringe PA based on established medical necessity for the prefilled (Toujeo®) pen. Addition; requires PA Insulin human inhalation powder is a rapid-acting insulin indicated to improve glycemic control in adult patients with Insulin human inhalation powder diabetes mellitus. This agent requires PA based on established (Afrezza®) medical necessity for the formulation. Headache Therapy Agents Change in PA status; requires PA Butalbital-containing agents are FDA-approved to treat for all ages and quantities tension-type headaches. Due to the increased cost and the availability of butalbital/acetaminophen/caffeine as a less Butalbital 50 mg/acetaminophen costly alternative, butalbital/acetaminophen and 325 mg butalbital/aspirin/caffeine/codeine requires PA for all ages Butalbital/aspirin/caffeine/codeine and quantities. (Fiorinal®/Codeine) Kinase Inhibitors Change in PA status; requires PA Everolimus, everolimus
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Orange Book Cumulative Supplement 7 July 2006
    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • Bluecross Blueshield of Western New York Formulary 1 Please Bring This Guide with You the Next Time You Visit Your Doctor
    BlueCross BlueShield of Western New York Formulary 1 Please bring this guide with you the next time you visit your doctor. If you have questions about your prescription drug benefit, visit the Pharmacy Services section of the BlueCross BlueShield web site at www.bcbswny.com. CRP2107_009678.1 MG009678A (Revise Date 07/01/2021) A Division of HealthNow New York Inc. An independent licensee of the BlueCross BlueShield Association. The Cross and Shield are registered trademarks of the BlueCross BlueShield Association. Inside front cover TABLE OF CONTENTS INTRODUCTION . iii UNDERSTANDING THE SYMBOLS USED THROUGHOUT THIS BOOK . iii USING THIS FORMULARY BOOK TO HELP CONTAIN COSTS . iv Save Money on Your Prescription Drugs . iv Finding Medications in the Guide . v SECTION 1 — THERAPEUTIC DRUG CATEGORIES . 1 SECTION II — INDEX . 8 ii The BlueCross BlueShield of Western New York Formulary 1 is a list of drugs to help guide physicians and pharmacists to select the medication that provides the appropriate treatment for the best price. INTRODUCTION BlueCross Blue Shield of Western New York has established an independent committee of practicing physicians and a pharmacist to help ensure that our formularies are medically sound and that they support your patients’ health. This committee—called the Pharmacy and Therapeutics Committee—reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. UNDERSTANDING THE SYMBOLS USED THROUGHOUT THIS BOOK Throughout this book, you will see certain symbols that indicate a management program is in place for selected medications. The symbols are as follows: Key P = A step edit applies to this drug.
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Updates in Pediatric Dermatology
    Peds Derm Updates ELIZABETH ( LISA) SWANSON , M D ADVANCED DERMATOLOGY COLORADO ROCKY MOUNTAIN HOSPITAL FOR CHILDREN [email protected] Disclosures Speaker Sanofi Regeneron Amgen Almirall Pfizer Advisory Board Janssen Powerpoints are the peacocks of the business world; all show, no meat. — Dwight Schrute, The Office What’s New In Atopic Dermatitis? Impact of Atopic Dermatitis Eczema causes stress, sleeplessness, discomfort and worry for the entire family Treating one patient with eczema is an example of “trickle down” healthcare Patients with eczema have increased risk of: ADHD Anxiety and Depression Suicidal Ideation Parental depression Osteoporosis and osteopenia (due to steroids, decreased exercise, and chronic inflammation) Impact of Atopic Dermatitis Sleep disturbances are a really big deal Parents of kids with atopic dermatitis lose an average of 1-1.5 hours of sleep a night Even when they sleep, kids with atopic dermatitis don’t get good sleep Don’t enter REM as much or as long Growth hormone is secreted in REM (JAAD Feb 2018) Atopic Dermatitis and Food Allergies Growing evidence that food allergies might actually be caused by atopic dermatitis Impaired barrier allows food proteins to abnormally enter the body and stimulate allergy Avoiding foods can be harmful Proper nutrition is important Avoidance now linked to increased risk for allergy and anaphylaxis Refer severe eczema patients to Allergist before 4-6 mos of age to talk about food introduction Pathogenesis of Atopic Dermatitis Skin barrier
    [Show full text]